Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2% - Time to Sell?

Key Points

• Sana Biotechnology shares fell 6.2% to $3.845, with trading volume down 90% from the average session volume.
• Analyst sentiment remains mixed but leans positive: seven analysts rate the stock a Buy, one rates it Hold, and one rates it Sell. The consensus rating is “Moderate Buy,” with an average price target of $9.33 versus the current price.
• The clinical-stage biotech exceeded quarterly earnings expectations, reporting a loss of $0.13 per share versus the consensus loss estimate of $0.15. Institutional investors own 88.23% of the company, and several hedge funds recently increased their positions.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report)'s stock price traded down 6.2% during trading on Thursday . The stock traded as low as $3.84 and last traded at $3.8450. 306,599 shares were traded during trading, a decline of 90% from the average session volume of 3,117,871 shares. The stock had previously closed at $4.10.

Analyst Upgrades and Downgrades

SANA has been the topic of a number of research reports. Weiss Ratings raised shares of Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, July 23rd. Bank of America dropped their price target on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating for the company in a research note on Friday, August 14th. Wall Street Zen lowered shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a report on Monday, July 20th. Finally, Rodman & Renshaw initiated coverage on shares of Sana Biotechnology in a research note on Monday, May 11th. They issued a "buy" rating and a $16.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $9.33.

Sana Biotechnology Stock Performance

The stock's 50 day moving average price is $3.43 and its 200 day moving average price is $3.42. The company has a market capitalization of $1.15 billion, a P/E ratio of -5.06 and a beta of 2.16.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. On average, analysts expect that Sana Biotechnology, Inc. will post -0.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC lifted its stake in shares of Sana Biotechnology by 49.8% in the 1st quarter. AQR Capital Management LLC now owns 573,146 shares of the company's stock valued at $963,000 after purchasing an additional 190,483 shares during the period. Woodline Partners LP grew its stake in Sana Biotechnology by 13.1% during the first quarter. Woodline Partners LP now owns 780,656 shares of the company's stock worth $1,312,000 after purchasing an additional 90,515 shares during the period. Franklin Resources Inc. grew its stake in Sana Biotechnology by 86.8% during the second quarter. Franklin Resources Inc. now owns 93,081 shares of the company's stock worth $254,000 after purchasing an additional 43,247 shares during the period. Rhumbline Advisers lifted its stake in Sana Biotechnology by 11.6% in the second quarter. Rhumbline Advisers now owns 203,283 shares of the company's stock valued at $555,000 after buying an additional 21,149 shares during the period. Finally, Prudential Financial Inc. acquired a new position in Sana Biotechnology in the second quarter valued at approximately $50,000. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source